NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016

Area of Science:

• Oncology
• Immunotherapy
• Clinical Guidelines

Background:

• Non-Small Cell Lung Cancer (NSCLC) remains a leading cause of cancer mortality.
• Traditional chemotherapy has limitations in efficacy and tolerability for advanced NSCLC.
• Recent advancements in immunotherapy have shown promise in treating various cancers.

Purpose of the Study:

• To summarize key updates from the 2016 NCCN Guidelines for NSCLC.
• To highlight the recommended use of novel immunotherapeutic agents.
• To provide guidance on second-line and subsequent therapy for metastatic NSCLC.

Main Methods:

• Review of the 2016 NCCN Guidelines for NSCLC (Versions 1-4).
• Focus on recommendations for immunotherapeutic agents, specifically nivolumab and pembrolizumab.
• Analysis of comparative data against docetaxel for efficacy and safety.

Main Results:

• Immune checkpoint inhibitors (nivolumab, pembrolizumab) are recommended as preferred agents for second-line and beyond therapy in metastatic NSCLC.
• These agents are recommended for both squamous and nonsquamous NSCLC histologies.
• Nivolumab and pembrolizumab demonstrated improved overall survival, response rates, and duration of response compared to docetaxel, with fewer adverse events.

Conclusions:

• The 2016 NCCN guidelines reflect a significant shift towards immunotherapy in advanced NSCLC treatment.
• Immune checkpoint inhibitors represent a preferred therapeutic option over docetaxel for subsequent lines of therapy.
• These updates offer improved treatment strategies for patients with metastatic NSCLC, enhancing survival and quality of life.